MX2023003890A - Molecula de interleucina-2 (il-2) modificada y uso de la misma. - Google Patents
Molecula de interleucina-2 (il-2) modificada y uso de la misma.Info
- Publication number
- MX2023003890A MX2023003890A MX2023003890A MX2023003890A MX2023003890A MX 2023003890 A MX2023003890 A MX 2023003890A MX 2023003890 A MX2023003890 A MX 2023003890A MX 2023003890 A MX2023003890 A MX 2023003890A MX 2023003890 A MX2023003890 A MX 2023003890A
- Authority
- MX
- Mexico
- Prior art keywords
- molecule
- modified
- il15rî
- mediates
- binding
- Prior art date
Links
- 108010002350 Interleukin-2 Proteins 0.000 abstract 5
- 239000000833 heterodimer Substances 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente solicitud describe una molécula de interleucina-2 (IL-2) modificada, donde la modificación incluye la sustitución de una región en una molécula IL-2 que media el enlace de la molécula IL-2 al receptor de interleucina-2 alfa (IL2Ra) con una región en una molécula de interleucina-15 (IL-15) que media el enlace de la molécula IL-15 al receptor de interleucina-15 alfa (IL15Ra). La región en la molécula IL-15 que media el enlace de la molécula IL-15 al IL15Ra incluye 9 o más residuos de aminoácido. La presente solicitud también describe un heterodímero de proteína que incluye la molécula IL-2 modificada descrita en la presente solicitud e IL15Ra (un dominio Sushi) o una variante del mismo. La molécula IL-2 modificada y/o el heterodímero de proteína que incluye la IL-2 modificada significativamente reducen una afinidad de IL2Ra para reducir grandemente sus efectos secundarios en el tratamiento clínico y es un candidato de fármaco prometedor.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011113975 | 2020-10-18 | ||
CN202111201233.4A CN114380919A (zh) | 2020-10-18 | 2021-10-15 | 经修饰的il-2分子及其用途 |
PCT/CN2021/124246 WO2022078518A1 (zh) | 2020-10-18 | 2021-10-16 | 经修饰的il-2分子及其用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023003890A true MX2023003890A (es) | 2023-04-24 |
Family
ID=81194547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023003890A MX2023003890A (es) | 2020-10-18 | 2021-10-16 | Molecula de interleucina-2 (il-2) modificada y uso de la misma. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230416326A1 (es) |
EP (1) | EP4230646A4 (es) |
JP (1) | JP2023545839A (es) |
KR (1) | KR20230096981A (es) |
CN (1) | CN114380919A (es) |
AU (1) | AU2021359560A1 (es) |
BR (1) | BR112023005610A2 (es) |
CA (1) | CA3197464A1 (es) |
GB (1) | GB2613483A (es) |
MX (1) | MX2023003890A (es) |
WO (1) | WO2022078518A1 (es) |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005085282A1 (en) * | 2004-02-27 | 2005-09-15 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Il-15 binding site for il15-ralpha and specific il-15 mutants having agonists/antagonists activity |
US20070160578A1 (en) * | 2005-12-14 | 2007-07-12 | The Gov. Of The Usa As Represented By The Secretary Of The Dep. Of Health And Human Services | Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes |
CN105440123B (zh) * | 2011-02-10 | 2020-10-09 | 罗切格利卡特公司 | 突变体白介素-2多肽 |
KR20130118941A (ko) * | 2011-02-10 | 2013-10-30 | 로슈 글리카트 아게 | 면역치료법 |
CN110437339B (zh) * | 2018-05-04 | 2021-08-13 | 免疫靶向有限公司 | 一种以白介素15为活性成分的融合蛋白型药物前体 |
SG11202011460YA (en) * | 2018-06-25 | 2020-12-30 | Univ Washington | De novo design of potent and selective interleukin mimetics |
CN112105634B (zh) * | 2018-09-21 | 2024-03-12 | 信达生物制药(苏州)有限公司 | 新型白介素2及其用途 |
TW202034945A (zh) * | 2018-12-21 | 2020-10-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種人白細胞介素2變體或其衍生物 |
CN111647068A (zh) * | 2019-03-04 | 2020-09-11 | 江苏恒瑞医药股份有限公司 | 一种人白细胞介素2变体或其衍生物 |
CN114478743A (zh) | 2019-12-17 | 2022-05-13 | 北京志道生物科技有限公司 | 白介素-2衍生物 |
CA3175717A1 (en) * | 2020-03-19 | 2021-09-23 | Innovent Biologics (Suzhou) Co., Ltd. | Interleukin-2 mutant and use thereof |
-
2021
- 2021-10-15 CN CN202111201233.4A patent/CN114380919A/zh active Pending
- 2021-10-16 GB GB2302511.7A patent/GB2613483A/en active Pending
- 2021-10-16 CA CA3197464A patent/CA3197464A1/en active Pending
- 2021-10-16 WO PCT/CN2021/124246 patent/WO2022078518A1/zh active Application Filing
- 2021-10-16 AU AU2021359560A patent/AU2021359560A1/en active Pending
- 2021-10-16 MX MX2023003890A patent/MX2023003890A/es unknown
- 2021-10-16 KR KR1020237010750A patent/KR20230096981A/ko unknown
- 2021-10-16 EP EP21879559.9A patent/EP4230646A4/en active Pending
- 2021-10-16 BR BR112023005610A patent/BR112023005610A2/pt unknown
- 2021-10-16 US US18/029,673 patent/US20230416326A1/en active Pending
- 2021-10-16 JP JP2023523307A patent/JP2023545839A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN114380919A (zh) | 2022-04-22 |
AU2021359560A1 (en) | 2023-03-23 |
WO2022078518A1 (zh) | 2022-04-21 |
GB202302511D0 (en) | 2023-04-05 |
CA3197464A1 (en) | 2022-04-21 |
BR112023005610A2 (pt) | 2023-05-09 |
KR20230096981A (ko) | 2023-06-30 |
US20230416326A1 (en) | 2023-12-28 |
GB2613483A (en) | 2023-06-07 |
JP2023545839A (ja) | 2023-10-31 |
EP4230646A4 (en) | 2024-04-03 |
EP4230646A1 (en) | 2023-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0207749A (pt) | Bactérias do ácido láctico como agentes para tratar e prevenir alergias | |
PL1873166T3 (pl) | Ulepszone dimery sgp 130Fc | |
RU2013114743A (ru) | Композиции и способы для топического нанесения и трансдермальной доставки ботулинических токсинов | |
ATE196428T1 (de) | Verwendung von gentisinsäure oder gentisylalkohol zur stabilisierung von radio-markierten peptiden und proteinen | |
EA200800050A1 (ru) | Самобуферирующиеся композиции белков | |
KR960701653A (ko) | 펩타이드 yy의 유사체 및 그의 용도 | |
HRP20110242T1 (hr) | Formulacija s fuzijskim proteinom glp-1-fc | |
MXPA03001673A (es) | Bacteria de acido lactico capaz de reducir una tendencia individual a desarrollar reacciones alergicas. | |
DE60106002D1 (de) | Behandlung von hematopoietischen zellen mit cxcr4 agonisten | |
BRPI0407533A (pt) | proteìnas de fusão e muteìnas do interferon alfa com propriedades melhoradas | |
YU53803A (sh) | Peptidi i/ili proteini kao i njihova primena za pripremanje terapeutskih i/ili preventivnih lekova | |
WO2004004750A3 (de) | Verwendung von inhibitoren der alanyl-aminopeptidasen und diese umfassende pharmazeutischen zubereitungen | |
MX2023003890A (es) | Molecula de interleucina-2 (il-2) modificada y uso de la misma. | |
DE60227670D1 (de) | Aminosäuren-enthaltende zusammensetzungen, geeignet zur wundheilung, insbesondere zur behandlung des auges | |
MX2022012525A (es) | Composiciones y metodos para el tratamiento de trastornos de agregacion de proteinas. | |
ATE355302T1 (de) | N-substituierte d-aminosäuren enthaltende peptide,zur prävention der beta-strang assoziation | |
MXPA04001655A (es) | Derivados de acido ascorbico, metodos de sintesis y uso farmaceutico de los mismos. | |
Block et al. | Amino acids in posterior pituitary protein | |
HK100597A (en) | Modified platelet factor-4 | |
SE9402331D0 (sv) | New use | |
PT804182E (pt) | Utilizacao de gabapentina para o tratamento da ansiedade e do panico | |
CN112972287A (zh) | 一种改善皮肤弹性的蛋白复配液及其制备方法和应用 | |
DE60125809D1 (de) | Diastereomere peptide und diese umfassende arzneimittel | |
Tavano et al. | Food proteins as a tool in human longevity: a mini-review | |
UA91497C2 (ru) | ПРИМЕНЕНИЕ ПЕПТИДОВ, ВЫДЕЛЕННЫХ ИЗ ЦЕПИ Bb ЧЕЛОВЕЧЕСКОГО ФИБРИНОГЕНА, ДЛЯ ЛЕЧЕНИЯ ШОКА |